Shares of Trevena (NASDAQ: TRVN) soared 31.5% on Monday after the biopharmaceutical company announced regulatory approval of its new pain-management treatment.
Trevena said the U.S. Food and Drug Administration (FDA) approved its new opioid agonist, called Olinvyk, for the management of acute pain in adults severe enough to require an intravenous opioid pain reliever -- and for whom other treatments are insufficient.
Trevena's stock soared on excitement for its new pain-relieving drug. Image source: Getty Images.
Source Fool.com